Investigating the role of the immune checkpoint receptor TIGIT in T cells during HIV disease progression and as a target for immune restoration

G. Chew¹, T. Fujita², K. Clayton³, N. Ishii², M. Abdel-Mohsen⁴, T. Liegler⁴, F. Hecht⁴, M. Ostrowski³, C. Shikuma⁵, M. Maurer⁶, A. Korman⁶, S. Deeks⁴, L. Ndhlovu¹

¹University of Hawaii, Manoa, Department of Tropical Medicine, Medical Microbiology, and Pharmacology, Honolulu, United States, ²Tohoku University, Department of Microbiology and Immunology, Sendai, Japan, ³University of Toronto, Department of Immunology, Toronto, Canada, ⁴University of California, San Francisco, Department of Medicine, San Francisco, United States, ⁵University of Hawaii, Manoa, Hawaii Center for HIV/AIDS, Honolulu, United States, ⁶Bristol-Myers Squibb, Biologics Discovery California, Redwood City, United States

Background: HIV infection induces a series of phenotypic and functional changes to T cells that eventually result in a state of T cell exhaustion and failure to control viral replication. T-cell-Ig-and-ITIM-domain (TIGIT) is a recently described negative checkpoint receptor expanded on CD8+ T cells during LCMV infection in mice and inhibits anti-viral effector CD8+ T cell activity. We hypothesized that during progressive HIV infection, TIGIT surface expression will mark an expanded population of dysfunctional T cells, and that novel monoclonal antibodies targeting TIGIT would restore anti-HIV-specific T cell responses.

Methods: Surface expression of TIGIT and PD-1 on T cells were measured by flow cytometry from 103 HIV-infected participants [non-controllers (n=20), elite controllers (n=20), antiretroviral (ART) suppressed (n=39), acutely infected (n=24)] and 20 age and gender matched HIV-uninfected controls. Quantified cell associated HIV (CA-HIV) DNA and RNA from purified CD4+ T cells. Functional characterization of TIGIT+ T cells was performed and ex-vivo HIV-specific cytokine and proliferative responses were assessed in the presence monoclonal antibodies (mAb) targeting TIGIT and/or PD-1 pathways (anti-TIGIT mAb and anti-PD-L1 mAb).

Results: In controls a median of 28.05% of CD8+ T cells were TIGIT+ (IQR 24.43,39.15). In comparison, we found a significant expansion of TIGIT+CD8+ T cells during chronic (median 57.1%, IQR 42.6,63.45; p< 0.0001) and a non-significant trend in acute HIV infection (40.40%, 28.3,47.8; p=0.08). TIGIT expression remained elevated despite viral suppression and associated with CD4+ CA-HIV DNA. TIGIT+ and TIGIT+PD-1+ CD8+ T cells inversely correlated with CD4 count (p=0.0016, r=-0.658; p=0.0024, r=-0.385 respectively). TIGIT was expressed on >50% HIV-specific CD8+ T cells, however TIGIT+ T cells failed to produce cytokines in response to HIV antigens. Single blockade of TIGIT led to a significant increase of interferon gamma response to HIV Gag compared to no blockade (p=0.027). Co-blockade of TIGIT and PD-L1 lead to greater restoration of HIV-specific CD8+ T cell proliferative responses (4.10%, IQR 1.46,22.28) than single blockade of TIGIT (3.47, IQR 1.11,10.08; p=0.0078) or PD-L1 (3.945%, IQR 1.15,17.53; p=0.039).

Conclusions: These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells and suggest TIGIT along with other checkpoint receptors may be novel curative HIV targets.

Under embargo until 14.30 on 21 July 2015